Zobrazeno 1 - 10
of 3 629
pro vyhledávání: '"Nasopharyngeal cancer"'
Autor:
Alexandru Aristide Alexe, Mihai Victor Lupascu, Haldun Septar, Anca Pantea Stoian, Andra Iulia Suceveanu, Viorel Gherghina, Iuliana Cindea, Alina Doina Nicoara, Laura Mazilu, Razvan Hainarosie, Felix Voinea, Adrian Paul Suceveanu
Publikováno v:
Journal of Mind and Medical Sciences, Vol 11, Iss 2, Pp 437-443 (2024)
Malignant nasopharyngeal tumors account for approximately 4% of ENT malignant tumor pathology and 1% of all cancers. The diagnosis of nasopharyngeal tumors is often late, the reason being the location in a silent anatomical region in terms of symptom
Externí odkaz:
https://doaj.org/article/c516ff5bbd064c89afbcc3c40f2bf778
Autor:
Santa Sheila, Brown Charles Adoquaye, Akakpo Patrick Kafui, Edusei Lawrence, Hooper Andrew Richard, Quaye Osbourne, Tagoe Emmanuel Ayitey
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 40, Iss 9, Pp 830-836 (2024)
Abstract Human papillomavirus (HPV)‐related cervical and nasopharyngeal cancers differ in molecular mechanisms underlying the oncogenic processes. The disparity may be attributed to differential expression of oncoproteins. The current study investi
Externí odkaz:
https://doaj.org/article/fc2f11b03e574b21917323fdaca7d6d8
Publikováno v:
BMC Immunology, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Introduction Metronomic capecitabine used as an adjuvant therapy improves survival in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). This therapeutic approach may also contribute to improving immune function, conseq
Externí odkaz:
https://doaj.org/article/a46fd3f8cfb740a4b03d826df69c8031
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 13, Pp 173-182 (2024)
Handoko,1– 3,* Marlinda Adham,2,4,* Lisnawati Rachmadi,2,5,* Heri Wibowo,6,* Soehartati A Gondhowiardjo1,2,* 1Department of Radiation Oncology, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; 2Faculty of Medici
Externí odkaz:
https://doaj.org/article/b8c3be2e262346068c1b3cf4e47b3399
Autor:
Martin Leu, Hanibal Bohnenberger, Manuel Guhlich, Markus Anton Schirmer, Yiannis Pilavakis, Hendrik Andreas Wolff, Stefan Rieken, Leif Hendrik Dröge
Publikováno v:
Cancer Reports, Vol 7, Iss 8, Pp n/a-n/a (2024)
Abstract Background and Aim The German NPC‐GPOH trials introduced treatment including neoadjuvant chemotherapy, radiochemotherapy (RCT) and antiviral treatment in patients aged 25 years or younger with nasopharyngeal cancer (NPC). We conducted a re
Externí odkaz:
https://doaj.org/article/212756e107064bf7a509eb55d7510d11
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeRadiation encephalopathy (REP) is one of the most common complications of radiotherapy for malignant tumors of the head and neck. Symptoms usually appear months to years following radiotherapy, with headache, insomnia, and memory loss as the m
Externí odkaz:
https://doaj.org/article/bdcb1c196c404bd19f7dc90566139698
Autor:
Shuling Shi, Bingyan Li, Pengcheng Zhou, Linhui Chen, Huizhen Li, Yingyi Wang, Xiaoyu Deng, Qianqian Dang, Jingjing Wu, Boya Zha, Peihong Li, Yingjuan Zheng, Daoke Yang
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Objective To analyze the efficacy and adverse effects of anti‐PD‐1 immune checkpoint inhibitors aimed at nasopharyngeal carcinoma (NPC). Methods During the first stage of the study, using 40 patients with stage III/IVa NPC treated with a
Externí odkaz:
https://doaj.org/article/eb1bcefdabd34e0c98f940afcf24f7a5
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Circular RNAs (circRNAs) constitute a class of endogenous non-coding RNAs (ncRNAs) that lack a 5’-ended cap and 3’-ended poly (A) tail and form a closed ring structure with covalent bonds. Due to its special structure, circRNA is resistant to Exo
Externí odkaz:
https://doaj.org/article/d6ff8456544e4ec2acf753fb6fa7b9d6
Autor:
Caroline Stella Vania Lay, Minidian Fasitasari, Febe Christianto, Niken Puruhita, Enny Probosari, Etisa Adi Murbawani
Publikováno v:
Human Nutrition & Metabolism, Vol 36, Iss , Pp 200261- (2024)
Background: Nasopharyngeal Cancer (NPC) patients experience a deficiency immune system due to a systemic inflammatory response. Anorexia due to inflammation and dysphagia, as well as the effects of therapy such as chemotherapy and radiotherapy in NPC
Externí odkaz:
https://doaj.org/article/ac2ed5a29c504dc4a2b884753b92824f
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC). We aimed to assess the cost-effectiveness of pembrolizuma
Externí odkaz:
https://doaj.org/article/b435492cf12a458aac678af5d558e2e8